Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies

Optimal two-stage designs for phase II clinical trials.

Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · see citing works

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

Balch, C. M., Buzaid, A. C., Soong, S., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A. N., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3635 · Cited by 2,627 · see citing works

iNOS-mediated nitric oxide production and its regulation

Aktan, F. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.10.042 · Cited by 1,364 · see citing works

Management of Cutaneous Melanoma

Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 857 · see citing works

Histone Deimination Antagonizes Arginine Methylation

Cuthbert, G. L., Daujat, S., Snowden, A. W., Erdjument‐Bromage, H., Hagiwara, T., Yamada, M., Schneider, R., Gregory, P. D., Tempst, P., Bannister, A. J., et al. (2004) · Cell · doi:10.1016/j.cell.2004.08.020 · Cited by 840 · see citing works

Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma

Lens, M. B., & Dawes, M. G. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.05708.x · Cited by 570 · see citing works

A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma

Kirkwood, J. M., Manola, J. B., Ibrahim, J. G., Sondak, V. K., Ernstoff, M. S., & Rao, U. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1103-3 · Cited by 550 · see citing works

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

Eggermont, A. M. M., & Kirkwood, J. M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.04.030 · Cited by 384 · see citing works

Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia

de Vries, E., Bray, F., Coebergh, J. W. W., Parkin, D. M., & European Network of Cancer Registries (2003) · International Journal of Cancer · doi:10.1002/ijc.11360 · Cited by 377 · see citing works

Regulation of Nitric Oxide Production by Arginine Metabolic Enzymes

Mori, M., & Gotoh, T. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3169 · Cited by 346 · see citing works

Argininosuccinate synthetase from the urea cycle to the citrulline–NO cycle

Husson, A., Brasse‐Lagnel, C., Fairand, A., Renouf, S., & Lavoinne, A. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03559.x · Cited by 329 · see citing works

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials

Eigentler, T., Caroli, U. M., Radny, P., & Garbe, C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01280-4 · Cited by 323 · see citing works

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers

Dillon, B. J., Prieto, V. G., Curley, S. A., Ensor, M., Holtsberg, F. W., Bomalaski, J. S., & Clark, M. A. (2004) · Cancer · doi:10.1002/cncr.20057 · Cited by 317 · see citing works

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.

Ensor, M., Holtsberg, F. W., Bomalaski, J. S., & Clark, M. A. (2002) · PubMed · Cited by 315 · see citing works

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies

Izzo, F., Marra, P., Beneduce, G., Castello, G., Vallone, P., De Rosa, V., Cremona, F., Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.120 · Cited by 250 · see citing works

I. Arginine

Tapiero, H., Mathé, G., Couvreur, P., & Tew, K. D. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(02)00284-6 · Cited by 249 · see citing works

Cancer immunotherapy: The interferon-α experience

Kirkwood, J. M. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.33078 · Cited by 213 · see citing works

Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties

Holtsberg, F. W., Ensor, M., Steiner, M. R., Bomalaski, J. S., & Clark, M. A. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00042-1 · Cited by 155 · see citing works

New TNM melanoma staging system: Linking biology and natural history to clinical outcomes

Balch, C. M., Buzaid, A. C., Soong, S., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A. N., Kirkwood, J. M., et al. (2003) · Seminars in Surgical Oncology · doi:10.1002/ssu.10020 · Cited by 124 · see citing works

In vivo anti‐tumor activity of arginine deiminase purified from Mycoplasma arginini

Takaku, H., Takase, M., Abe, S., Hayashi, H., & Miyazaki, K. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510213 · Cited by 123 · see citing works

Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines

Simon, R. M., Steinberg, S. M., Hamilton, M., Hildesheim, A., Khleif, S. N., Kwak, L. W., Mackall, C. L., Schlom, J., Topalian, S. L., & Berzofsky, J. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1848 · Cited by 113 · see citing works

Systemic chemotherapy in the treatment of malignant melanoma

Lens, M. B., & Eisen, T. G. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.12.2205 · Cited by 98 · see citing works

Antiapoptotic role of endogenous nitric oxide in human melanoma cells.

Salvucci, O., Carsana, M., Bersani, I., Tragni, G., & Anichini, A. (2001) · PubMed · Cited by 97 · see citing works

Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth

Is, P., Kang, S.-W., Shin, Y.-J., Chae, K.-Y., Park, M.-O., Kim, M. Y., Wheatley, D. N., & Min, B.-H. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601181 · Cited by 95 · see citing works

Anti‐tumor Activity of Arginine Deiminase from Mycoplasma arginini and Its Growth‐inhibitory Mechanism

Takaku, H., Matsumoto, M., Misawa, S., & Miyazaki, K. (1995) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1995.tb03094.x · Cited by 89 · see citing works

High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro

Sugimura, K., Ohno, T., Kusuyama, T., & Azuma, I. (1992) · Melanoma Research · doi:10.1097/00008390-199209000-00007 · Cited by 83 · see citing works

Arginine Deiminase Inhibits Cell Proliferation by Arresting Cell Cycle and Inducing Apoptosis

Gong, H., Zölzer, F., Recklinghausen, G. V., Rössler, J. K., Breit, S., Havers, W., Fotsis, T., & Schweigerer, L. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1004 · Cited by 76 · see citing works

Controlling cancer by restricting arginine availability–arginine-catabolizing enzymes as anticancer agents

Wheatley, D. N. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200410000-00002 · Cited by 74 · see citing works

Role of Nitric Oxide in Tumor Angiogenesis

Morbidelli, L., Donnini, S., & Ziche, M. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-8871-3_11 · Cited by 70 · see citing works

Effect of dietary arginine restriction upon ornithine and polyamine metabolism during two-stage epidermal carcinogenesis in the mouse.

Gonzalez, G., & Byus, C. V. (1991) · PubMed · Cited by 69 · see citing works

Depletion of Dietary Arginine Inhibits Growth of Metastatic Tumor

Yeatman, T. J. (1991) · Archives of Surgery · doi:10.1001/archsurg.1991.01410350066010 · Cited by 67 · see citing works

Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production.

Dillon, B. J., Holtsberg, F. W., Ensor, M., Bomalaski, J. S., & Clark, M. A. (2002) · PubMed · Cited by 57 · see citing works

Chemopreventive Effects of a Selective Nitric Oxide Synthase Inhibitor on Carcinogen-Induced Rat Esophageal Tumorigenesis

Chen, T., Nines, R. G., Peschke, S. M., Kresty, L. A., & Stoner, G. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0302 · Cited by 56 · see citing works

The Effect of Arginase on the Retardation of Tumour Growth

Bach, S. J., & Swaine, D. (1965) · British Journal of Cancer · doi:10.1038/bjc.1965.45 · Cited by 55 · see citing works

Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: Potentiation by irradiation

Gong, H., Pöttgen, C., Stüben, G., Havers, W., Stuschke, M., & Schweigerer, L. (2003) · International Journal of Cancer · doi:10.1002/ijc.11298 · Cited by 53 · see citing works

The best way to use asparaginase in childhood acute lymphatic leukaemia – still to be defined?

Pinheiro, J. P. V., & Boos, J. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04863.x · Cited by 52 · see citing works

Characterization of Mycoplasma Arginine Deiminase Expressed in E. coli and Its Inhibitory Regulation of Nitric Oxide Synthesis

Noh, E. J., Kang, S. W., Shin, Y. J., Kim, D. C., Park, I. S., Kim, M. Y., Chun, B. G., & Min, B.-H. (2002) · Molecules and Cells · doi:10.1016/s1016-8478(23)15015-1 · Cited by 49 · see citing works

Adjuvant therapy of melanoma

Agarwala, S. S., & Kirkwood, J. M. (1998) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(199806)14:4 · Cited by 46 · see citing works

Evidence that a rat liver “inhibitor” of the synthesis of DNA in cultured mammalian cells is arginase

Holley, R. W. (1967) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(67)90076-7 · Cited by 43 · see citing works

Arginine deiminase enhances dexamethasone‐induced cytotoxicity in human T‐lymphoblastic leukemia CCRF‐CEM cells

Noh, E., Kang, S., Shin, Y., Choi, S., Kim, C., Park, I.-S., Wheatley, D. N., & Min, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20435 · Cited by 40 · see citing works

Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor α and endotoxin

THOMAS, J. B., Holtsberg, F. W., Ensor, M., Bomalaski, J. S., & Clark, M. A. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3630581 · Cited by 39 · see citing works

Chemical Modification by Polyethylene Glycol of the Anti‐tumor Enzyme Arginine Deiminase from Mycoplasma arginini

Takaku, H., Misawa, S., Hayashi, H., & Miyazaki, K. (1993) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1993.tb02821.x · Cited by 38 · see citing works

Apoptotic cell death of human T lymphoblastoid cells induced by arginine deiminase.

Komada (1997) · International Journal of Hematology · doi:10.1016/s0925-5710(96)00538-5 · Cited by 36 · see citing works

The influence of arginine upon the growth rate of a transplantable tumour in the mouse

Gilroy, E. (1930) · Biochemical Journal · doi:10.1042/bj0240589 · Cited by 35 · see citing works

Regression of hepatocellular cancer in a patient treated with arginine deiminase.

Curley, S. A., Bomalaski, J. S., Ensor, M., Holtsberg, F. W., & Clark, M. A. (2003) · PubMed · Cited by 34 · see citing works

Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor α and endotoxin

THOMAS, J. B., Holtsberg, F. W., Ensor, M., et al. (2002) · Biochemical Journal · doi:10.1042/bj3630581 · Cited by 34 · see citing works

Recombinant arginine deiminase as a differential modulator of inducible (iNOS) and endothelial (eNOS) nitric oxide synthetase activity in cultured endothelial cells

Shen, L., Lin, W., Beloussow, K., Hosoya, K., Terasaki, T., Ann, D. K., & Shen, W. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00555-0 · Cited by 32 · see citing works

Pemetrexed: Single-agent and combination phase I study overview

Boyer, M. J., Rivory, L. P., & Clarke, S. J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37464 · Cited by 16 · see citing works

Update on the systemic treatment of malignant melanoma

Lawson, D. H. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.02.014 · Cited by 14 · see citing works

The systemic treatment of advanced cutaneous melanoma

Logan, T. F. (2003) · Facial Plastic Surgery Clinics of North America · doi:10.1016/s1064-7406(02)00056-1 · Cited by 10 · see citing works

Phase II Trial of Paclitaxel and Dacarbazine with Filgrastim Administration in Advanced Malignant Melanoma

Feun, L. G., Savaraj, N., Hurley, J. E., & Marini, A. (2002) · Cancer Investigation · doi:10.1081/cnv-120001181 · Cited by 7 · see citing works

The role of biological response modifiers in malignant melanoma

Lens, M. B. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.8.1225 · Cited by 6 · see citing works

Adjuvant therapy of melanoma: what's new?

Ascierto, P. A., Palmieri, G., Daponte, A., Melucci, M. T., Satriano, R. A., Mozzillo, N., & Castello, G. (2002) · Melanoma Research · doi:10.1097/00008390-200206000-00015 · Cited by 4 · see citing works

Inhibitory effects of arginase on mammary adenocarcinoma transplants in strain "A" mice.

VRAT, V. (1951) · Permanente Foundation Medical Bulletin · Cited by 4 · see citing works

Factors affecting the clearance and biodistribution of polymeric nanoparticles

Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · see citing works

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez‐Herrero, E., & Fernández‐Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,888 · see citing works

Cancer metabolism: a therapeutic perspective

Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505 · see citing works

Targeting Metabolism for Cancer Therapy

Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971 · see citing works

Arginase: an emerging key player in the mammalian immune system

Munder, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00291.x · Cited by 701 · see citing works

Delivery of Therapeutic Proteins

Pisal, D. S., Kosloski, M. P., & Balu-Iyer, S. V. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22054 · Cited by 532 · see citing works

PEG conjugates in clinical development or use as anticancer agents: An overview

Pasut, G., & Veronese, F. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.02.010 · Cited by 458 · see citing works

Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer

Delage, B., Fennell, D. A., Nicholson, L., McNeish, I., Lemoine, N. R., Crook, T., & Szlosarek, P. W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25202 · Cited by 441 · see citing works

Immune resistance orchestrated by the tumor microenvironment

Gajewski, T. F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., & Harlin, H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00442.x · Cited by 437 · see citing works

Myeloid Cell-Derived Arginase in Cancer Immune Response

Grzywa, T. M., Sosnowska, A., Matryba, P., Rydzyńska, Z., Jasiński, M., Nowis, D., & Gołąb, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00938 · Cited by 434 · see citing works

PEGylation in anti-cancer therapy: An overview

Mishra, P., Nayak, B., & Dey, R. K. (2015) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2015.08.011 · Cited by 383 · see citing works

Nanoparticle Technologies for Cancer Therapy

Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00477-3_2 · Cited by 372 · see citing works

Rewiring urea cycle metabolism in cancer to support anabolism

Keshet, R., Szlosarek, P. W., Carracedo, A., & Erez, A. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0054-z · Cited by 322 · see citing works

Arginine Deiminase as a Novel Therapy for Prostate Cancer Induces Autophagy and Caspase-Independent Apoptosis

Kim, R. H., Coates, J. M., Bowles, T. L., McNerney, G. P., Sutcliffe-Goulden, J., Jung, J. U., Gandour‐Edwards, R. F., Chuang, F. Y. S., Bold, R. J., & Kung, H.-J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3157 · Cited by 316 · see citing works

Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity

Rodrı́guez, P. C., Ochoa, A. C., & Al-Khami, A. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00093 · Cited by 287 · see citing works

Pegylated Recombinant Human Arginase (rhArg-peg5,000mw) Inhibits the In vitro and In vivo Proliferation of Human Hepatocellular Carcinoma through Arginine Depletion

Cheng, P., Lam, T. L., Lam, W.-M., Tsui, S. M., Cheng, A. W. M., Lo, W. H., & Leung, Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1945 · Cited by 279 · see citing works

Arginine dependence of tumor cells: targeting a chink in cancer’s armor

Patil, M. D., Bhaumik, J., Babykutty, S., Banerjee, U. C., & Fukumura, D. (2016) · Oncogene · doi:10.1038/onc.2016.37 · Cited by 268 · see citing works

Immune Suppression in the Tumor Microenvironment

Gajewski, T. F., Meng, Y., & Harlin, H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199193.29048.56 · Cited by 261 · see citing works

Amino acid metabolism in hematologic malignancies and the era of targeted therapy

Tabe, Y., Lorenzi, P. L., & Konopleva, M. Y. (2019) · Blood · doi:10.1182/blood.2019001034 · Cited by 238 · see citing works

Arginine Deprivation as a Targeted Therapy for Cancer

Feun, L. G., You, M., Wu, C., Kuo, M. T., Wangpaichitr, M., Spector, S. A., & Savaraj, N. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784246199 · Cited by 235 · see citing works

Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells

Tsai, W.-B., Aiba, I., Long, Y., Lin, H., Feun, L. G., Savaraj, N., & Kuo, M. T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3605 · Cited by 233 · see citing works

Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges

Phillips, M. M., Sheaff, M. T., & Szlosarek, P. W. (2013) · Cancer Research and Treatment · doi:10.4143/crt.2013.45.4.251 · Cited by 229 · see citing works

Arginine Starvation Impairs Mitochondrial Respiratory Function in ASS1-Deficient Breast Cancer Cells

Qiu, F., Chen, Y.-R., Liu, X., Chu, C.-Y., Shen, L., Xu, J., Gaur, S., Forman, H. J., Zhang, H., Zheng, S. S., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004761 · Cited by 218 · see citing works

The Diverse Functions of Non-Essential Amino Acids in Cancer

Choi, B.-H., & Coloff, J. L. (2019) · Cancers · doi:10.3390/cancers11050675 · Cited by 213 · see citing works

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma

Szlosarek, P. W., Steele, J. P. C., Nolan, L., Gilligan, D., Taylor, P. D., Spicer, J. F., Lind, M., Mitra, S. S., Shamash, J., Phillips, M. M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3049 · Cited by 203 · see citing works

IL‐8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer

Rotondo, R., Barisione, G., Mastracci, L., Grossi, F., Orengo, A. M., Costa, R., Truini, M., Fabbi, M., Ferrini, S., & Barbieri, O. (2009) · International Journal of Cancer · doi:10.1002/ijc.24448 · Cited by 198 · see citing works

Targeting amino acid metabolism in cancer growth and anti-tumor immune response

Ananieva, E. A. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.281 · Cited by 198 · see citing works

Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy

Changou, C. A., Chen, Y.-R., Xing, L., Yen, Y., Chuang, F. Y. S., Cheng, R. H., Bold, R. J., Ann, D. K., & Kung, H.-J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404171111 · Cited by 186 · see citing works

Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma

Glazer, E. S., Piccirillo, M., Albino, V., Giacomo, R. D., Palaia, R., Mastro, A. A., Beneduce, G., Castello, G., Rosa, V. D., Petrillo, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7765 · Cited by 187 · see citing works

In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion

Szlosarek, P. W., Klampatsa, A., Pallaska, A., Sheaff, M. T., Smith, P., Crook, T., Grimshaw, M. J., Steele, J. P. C., Rudd, R., Balkwill, F. R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1101 · Cited by 181 · see citing works

Argininosuccinate synthase: at the center of arginine metabolism.

(2011) · Europe PMC (PubMed Central) · Cited by 176 · see citing works

Arginine—Dual roles as an onconutrient and immunonutrient

Albaugh, V. L., Pinzon‐Guzman, C., & Barbul, A. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24490 · Cited by 173 · see citing works

Drug-induced amino acid deprivation as strategy for cancer therapy

Fung, M. K. L., & Chan, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0509-9 · Cited by 172 · see citing works

Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation<i>via</i>arginine deiminase

Yoon, C., Shim, Y., Kim, E., Lee, J., Won, N., Kim, J., Park, I., Yoon, D., & Min, B. (2007) · International Journal of Cancer · doi:10.1002/ijc.22322 · Cited by 165 · see citing works

Arginine and the metabolic regulation of nitric oxide synthesis in cancer

Keshet, R., & Erez, A. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.033332 · Cited by 159 · see citing works

Arginine metabolism and deprivation in cancer therapy

Zou, S., Wang, X., Liu, P., Ke, C., & Xu, S. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109210 · Cited by 159 · see citing works

Targeting arginine metabolism pathway to treat arginine-dependent cancers

Qiu, F., Huang, J., & Sui, M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.020 · Cited by 158 · see citing works

Metabolic pathways of L-arginine and therapeutic consequences in tumors

Szefel, J., Danielak, A., & Kruszewski, W. J. (2018) · Advances in Medical Sciences · doi:10.1016/j.advms.2018.08.018 · Cited by 155 · see citing works

Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

Bowles, T. L., Kim, R., Galante, J., Parsons, C. M., Virudachalam, S., Kung, H., & Bold, R. J. (2008) · International Journal of Cancer · doi:10.1002/ijc.23723 · Cited by 153 · see citing works

Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging

Allen, M. D., Luong, P., Hudson, C. D., Leyton, J., Delage, B., Ghazaly, E. A., Cutts, R. J., Yuan, M., Syed, N., Nigro, C. L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1702 · Cited by 153 · see citing works

Anti-cancer PEG-enzymes: 30 years old, but still a current approach

Pasut, G., Sergi, M., & Veronese, F. M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.018 · Cited by 152 · see citing works

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

Ott, P. A., Carvajal, R. D., Pandit-Taskar, N., Jungbluth, A. A., Hoffman, E. W., Wu, B.-W., Bomalaski, J. S., Venhaus, R., Pan, L., Old, L. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9862-2 · Cited by 146 · see citing works

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis

Delage, B., Luong, P., Maharaj, L., Ó’Riain, C., Syed, N., Crook, T., Hatzimichael, E. C., Papoudou‐Bai, A., Mitchell, T. J., Whittaker, S. J., et al. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.83 · Cited by 144 · see citing works

Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1α/Sp4

Tsai, W.-B., Aiba, I., Lee, S.-Y., Feun, L. G., Savaraj, N., & Kuo, M. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0794 · Cited by 141 · see citing works

Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo

Miraki‐Moud, F., Ghazaly, E. A., Ariza‐McNaughton, L., Hodby, K. A., Clear, A. J., Anjos‐Afonso, F., Liapis, K., Grantham, M., Sohrabi, F., Cavenagh, J. D., et al. (2015) · Blood · doi:10.1182/blood-2014-10-608133 · Cited by 139 · see citing works

Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer

Nicholson, L. J., Smith, P. R., Hiller, L., Szlosarek, P. W., Kimberley, C., Sehouli, J., Koensgen, D., Mustea, A., Schmid, P., & Crook, T. (2009) · International Journal of Cancer · doi:10.1002/ijc.24546 · Cited by 133 · see citing works

Perioperative arginine-supplemented nutrition in malnourished patients with head and neck cancer improves long-term survival

Buijs, N., de van der Schueren, M. A. E., Langius, J. A. E., Leemans, C. R., Kuik, D. J., Vermeulen, M. A. R., & van Leeuwen, P. A. M. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29532 · Cited by 124 · see citing works

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers

Beddowes, E. J., Spicer, J. F., Chan, P. Y., Khadeir, R. S., Corbacho, J. G., Repana, D., Steele, J. P. C., Schmid, P., Szyszko, T. A., Cook, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3230 · Cited by 121 · see citing works

Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma

Kobayashi, E., Masuda, M., Nakayama, R. T., Ichikawa, H., Satow, R., Shitashige, M., Honda, K., Yamaguchi, U., Shoji, A., Tochigi, N., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0774 · Cited by 120 · see citing works

Pegylated arginine deiminase: a novel anticancer enzyme agent

Feun, L. G., & Savaraj, N. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.7.815 · Cited by 118 · see citing works

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase

Kelly, M. P., Jungbluth, A. A., Wu, B.-W., Bomalaski, J. S., Old, L. J., & Ritter, G. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.524 · Cited by 117 · see citing works

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

Feun, L. G., Marini, A., Walker, G., Elgart, G., Moffat, F., Rodgers, S. E., Wu, C. J., You, M., Wangpaichitr, M., Kuo, M. T., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.106 · Cited by 113 · see citing works

Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma

Savaraj, N., You, M., Wu, C., Wangpaichitr, M., Kuo, M. T., & Feun, L. G. (2010) · Current Molecular Medicine · doi:10.2174/156652410791316995 · Cited by 108 · see citing works

Pegylated arginase I: a potential therapeutic approach in T-ALL

Hernandez, C. P., Morrow, K. D., Lopez-Barcons, L. A., Zabaleta, J., Sierra, R. A., Velasco, C., COLE, J. T., & Rodrı́guez, P. C. (2010) · Blood · doi:10.1182/blood-2009-12-258822 · Cited by 104 · see citing works

A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma

Yau, T. C. C., Cheng, P. N.-M., Chan, P., Chan, W., Chen, L., Yuen, J. H. F., Pang, R. W. C., Fan, S. T., & Poon, R. T. P. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9807-9 · Cited by 104 · see citing works

The Relationship of Thioredoxin-1 and Cisplatin Resistance: Its Impact on ROS and Oxidative Metabolism in Lung Cancer Cells

Wangpaichitr, M., Sullivan, E. J., Theodoropoulos, G., Wu, C., You, M., Feun, L. G., Lampidis, T. J., Kuo, M. T., & Savaraj, N. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0599 · Cited by 94 · see citing works

Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma

Sosnowska, A., Chlebowska, J., Matryba, P., Pilch, Z., Greig, A., Wolny, A., Grzywa, T. M., Rydzyńska, Z., Sokołowska, O., Rygiel, T. P., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1956143 · Cited by 92 · see citing works

Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors

Tomlinson, B. K., Thomson, J. A., Bomalaski, J. S., Diaz, M., Akande, T., Mahaffey, N., Li, T., Dutia, M. P., Kelly, K. L., Gong, I.-Y., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2610 · Cited by 91 · see citing works

Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections

Fernandes, H. S., Teixeira, C. S. S., Fernandes, P. A., Ramos, M. J., & Cerqueira, N. M. F. S. A. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1254194 · Cited by 91 · see citing works

Microbial-based therapy of cancer: Current progress and future prospects

Bernardes, N., Seruca, R., Chakrabarty, A. M., & Fialho, A. M. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.3.10903 · Cited by 88 · see citing works

Arginine-Depleting Enzymes – An Increasingly Recognized Treatment Strategy for Therapy-Refractory Malignancies

Riess, C., Shokraie, F., Classen, C. F., Kreikemeyer, B., Fiedler, T., Junghanß, C., & Maletzki, C. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495382 · Cited by 86 · see citing works

Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest

Lam, T. L., Wong, G., Chong, H.-C., Cheng, P. N.-M., Choi, S. C., Chow, T. L., Kwok, S.-Y., Poon, R. T. P., Wheatley, D. N., Lo, W., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.11.031 · Cited by 87 · see citing works

Deprivation of arginine by recombinant human arginase in prostate cancer cells

Hsueh, E. C., Knebel, S. M., Lo, W., Leung, Y., Cheng, P. N.-M., & Hsueh, C.-T. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-17 · Cited by 84 · see citing works

Dual-Porosity Hollow Nanoparticles for the Immunoprotection and Delivery of Nonhuman Enzymes

Ortac, I., Simberg, D., Yeh, Y.-S., Yang, J., Messmer, B. T., Trogler, W. C., Tsien, R. Y., & Esener, S. C. (2014) · Nano Letters · doi:10.1021/nl404360k · Cited by 79 · see citing works

Polyethyleneimine-Based Core-Shell Nanogels: A Promising siRNA Carrier for Argininosuccinate Synthetase mRNA Knockdown in HeLa Cells

Mimi, H., Ho, K. M., Siu, Y. S., Wu, A., & Li, P. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.035 · Cited by 79 · see citing works

Amino acid metabolism as a therapeutic target in cancer: a review

Endicott, M., Jones, M. J., & Hull, J. (2021) · Amino Acids · doi:10.1007/s00726-021-03052-1 · Cited by 75 · see citing works

Progress in the Management of Malignant Pleural Mesothelioma in 2017

McCambridge, A. J., Napolitano, A., Mansfield, A. S., Fennell, D. A., Sekido, Y., Nowak, A. K., Reungwetwattana, T., Mao, W., Pass, H. I., Carbone, M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.021 · Cited by 75 · see citing works

Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)

Tsui, S. M., Lam, W.-M., Lam, T. L., Chong, H.-C., So, P., Kwok, S.-Y., Arnold, S., Cheng, P. N.-M., Wheatley, D. N., Lo, W., et al. (2009) · Cancer Cell International · doi:10.1186/1475-2867-9-9 · Cited by 75 · see citing works

Metabolic Response to Pegylated Arginine Deiminase in Mesothelioma With Promoter Methylation of Argininosuccinate Synthetase

Szlosarek, P. W., Luong, P., Phillips, M. M., Baccarini, M., Ellis, S. M., Szyszko, T. A., Sheaff, M. T., & Avril, N. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.1784 · Cited by 74 · see citing works

TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation

You, M., Savaraj, N., Kuo, M. T., Wangpaichitr, M., Varona-Santos, J., Wu, C., Nguyen, D. M., & Feun, L. G. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1518-1 · Cited by 72 · see citing works

A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma

Hall, P. E., Lewis, R., Syed, N., Shaffer, R. E., Evanson, J., Ellis, S. M., Williams, M., Feng, X., Johnston, A. L., Thomson, J. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3729 · Cited by 70 · see citing works

Nitric Oxide and Its Gatekeeper Thrombospondin-1 in Tumor Angiogenesis

Roberts, D. D., Isenberg, J. S., Ridnour, L. A., & Wink, D. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1758 · Cited by 68 · see citing works

Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy

McAlpine, J. A., Lu, H.-T., Wu, K. C., Knowles, S. K., & Thomson, J. A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-621 · Cited by 67 · see citing works

Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells

Wang, Z., Shi, X., Li, Y., Fan, J., Zeng, X. L., Xian, Z., Wang, Z., Sun, Y., Wang, S., Song, P., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.503 · Cited by 67 · see citing works

Cancer cell metabolism: Rewiring the mitochondrial hub

Oliveira, G. L., Coelho, A. R., Marques, R., & Oliveira, P. J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166016 · Cited by 62 · see citing works

Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells

Khoury, O., Ghazale, N., Stone, E. M., El‐Sibai, M., Frankel, A. E., & Abi‐Habib, R. J. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1698-5 · Cited by 64 · see citing works

Insights into the Pathogenesis and Treatment of Cancer from Inborn Errors of Metabolism

Erez, A., Shchelochkov, O. A., Plon, S. E., Scaglia, F., & Lee, B. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.03.005 · Cited by 65 · see citing works

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma

Szlosarek, P. W., Creelan, B., Sarkodie, T., Nolan, L., Taylor, P. D., Olevsky, O. M., Grosso, F., Cortinovis, D. L., Chitnis, M. M., Roy, A., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.6789 · Cited by 61 · see citing works

Aberrant regulation of argininosuccinate synthetase by TNF‐α in human epithelial ovarian cancer

Szlosarek, P. W., Grimshaw, M. J., Wilbanks, G. D., Hagemann, T., Wilson, J. L., Burke, F., Stamp, G., & Balkwill, F. R. (2007) · International Journal of Cancer · doi:10.1002/ijc.22666 · Cited by 61 · see citing works

Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia

Habibi, D., Ogloff, N., Jalili, R. B., Yost, A., Weng, A. P., Ghahary, A., & Ong, C. J. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9700-y · Cited by 60 · see citing works

SCHEMA-Designed Variants of Human Arginase I and II Reveal Sequence Elements Important to Stability and Catalysis

Romero, P. A., Stone, E. M., Lamb, C., Chantranupong, L., Krause, A., Miklos, A. E., Hughes, R. A., Fechtel, B. M., Ellington, A. D., Arnold, F. H., et al. (2012) · ACS Synthetic Biology · doi:10.1021/sb300014t · Cited by 60 · see citing works

Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53

Miyamoto, T., Lo, P. H. Y., Saichi, N., Ueda, K., Hirata, M., Tanikawa, C., & Matsuda, K. (2017) · Science Advances · doi:10.1126/sciadv.1603204 · Cited by 59 · see citing works

Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines

Shan, Y., Hsu, H., Lai, M.-D., Yen, M., Chen, W.-C., Fang, J.-H., Weng, T., & Chen, Y. (2015) · Scientific Reports · doi:10.1038/srep09783 · Cited by 58 · see citing works

Arginine metabolism: a potential target in pancreatic cancer therapy

Yang, J., Wang, C., Qiu, J., Ren, B., & You, L. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001216 · Cited by 56 · see citing works

Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells

Tanios, R. F., Bekdash, A., Kassab, E., Stone, E. M., Georgiou, G., Frankel, A. E., & Abi‐Habib, R. J. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.08.007 · Cited by 55 · see citing works

Engineering Reduced-Immunogenicity Enzymes for Amino Acid Depletion Therapy in Cancer

Cantor, J. R., Panayiotou, V., Agnello, G., Georgiou, G., & Stone, E. M. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-416039-2.00015-x · Cited by 53 · see citing works

Arginine deprivation as a strategy for cancer therapy: An insight into drug design and drug combination

Zhang, Y., Chung, S., Tam, S.-Y., Leung, Y., & Guan, X. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.041 · Cited by 52 · see citing works

Arginine deprivation therapy for malignant melanoma

Kim, K., Yoon, Y., Frankel, A. E., Feun, & Ekmekcioglu (2012) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s37350 · Cited by 50 · see citing works

Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia

Morrow, K. D., Hernandez, C. P., Raber, P. L., Valle, L. D., Wilk, A. M., Majumdar, S., Wyczechowska, D. D., Krzysztof Reiss, F., & Rodrı́guez, P. C. (2012) · Leukemia · doi:10.1038/leu.2012.247 · Cited by 50 · see citing works

Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy

long, Y. N., Tsai, W.-B., Wang, D., Hawke, D. H., Savaraj, N., Feun, L. G., Hung, M., Chen, H. H. W., & Kuo, M. T. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.028 · Cited by 51 · see citing works

Amino Acid Degrading Enzymes and their Application in Cancer Therapy

Pokrovsky, V. S., Chepikova, O. E., Давыдов, Д. Ж., Zamyatnin, A. A., Lukashev, A. N., & Lukasheva, E. V. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666171006132729 · Cited by 50 · see citing works

Single amino acid arginine starvation efficiently sensitizes cancer cells to canavanine treatment and irradiation

Vynnytska‐Myronovska, B., Bobak, Y. P., Garbe, Y., Dittfeld, C., Stasyk, O. V., & Kunz‐Schughart, L. A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26221 · Cited by 48 · see citing works

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

Chang, K., Chiang, N., Wu, S., Yen, C.-J., Chen, S., Yeh, Y., Li, C., Feng, X., Wu, K., Johnston, A. L., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1943253 · Cited by 47 · see citing works

Expression, purification, and characterization of arginine deiminase from Lactococcus lactis ssp. lactis ATCC 7962 in Escherichia coli BL21

Kim, J., Jeong, D., & Lee, H. J. (2006) · Protein Expression and Purification · doi:10.1016/j.pep.2006.12.002 · Cited by 47 · see citing works

The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials

Synakiewicz, A., Stachowicz‐Stencel, T., & Adamkiewicz‐Drożyńska, E. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.934808 · Cited by 45 · see citing works

Research into cancer metabolomics: Towards a clinical metamorphosis

Olivares, O., Däbritz, J. H. M., King, A., Gottlieb, E., & Halsey, C. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.008 · Cited by 45 · see citing works

Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression

Rotondo, R., Mastracci, L., Piazza, T., Barisione, G., Fabbi, M., Cassanello, M., Costa, R., Morandi, B., Astigiano, S., Cesario, A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23437 · Cited by 45 · see citing works

Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma

Wu, L., Li, L., Meng, S.-C., Qi, R., Mao, Z., & Lin, M. T. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12043 · Cited by 44 · see citing works

Arginine deprivation induces endoplasmic reticulum stress in human solid cancer cells

Bobak, Y. P., Kurlishchuk, Y. V., Vynnytska‐Myronovska, B., Grydzuk, O., Shuvayeva, G., Rędowicz, M. J., Kunz‐Schughart, L. A., & Stasyk, O. V. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.10.027 · Cited by 44 · see citing works

Therapeutics targeting tumor immune escape: Towards the development of new generation anticancer vaccines

D, S. M. M., & Nitti, D. (2007) · Medicinal Research Reviews · doi:10.1002/med.20110 · Cited by 44 · see citing works

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

Ott, P. A., Carvajal, R. D., Pandit-Taskar, N., Jungbluth, A. A., Hoffman, E. W., Wu, B.-W., Bomalaski, J. S., Venhaus, R., Pan, L., Old, L. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9862-2 · Cited by 146 · see citing works

Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma (MM)

Ott, P. A., Carvajal, R. D., Pandit-Taskar, N. D., Jungbluth, A. A., Hoffman, E. W., Venhaus, R. R., Pan, L., Old, L. J., Pavlick, A. C., & Wolchok, J. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9030 · Cited by 5 · see citing works

Phase II study of pegylated arginine deiminase (ADI-PEG20), a novel targeted therapy for melanoma

Feun, L. G., Savaraj, N., Marini, A., Wu, C., Robles, C., Herrera, C., Spector, S. A., Luedemann, K., Moffat, F. L., & Bomalaski, J. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.8045 · Cited by 6 · see citing works

Pegylated arginine deiminase: a novel anticancer enzyme agent

Feun, L. G., & Savaraj, N. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.7.815 · Cited by 118 · see citing works

Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM).

Feun, L. G., You, M., Wu, C., Wangpaichitr, M., Kuo, M. T., Marini, A., Jungbluth, A., & Savaraj, N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8528 · Cited by 9 · see citing works